Data Sources Policy

Nexvora LLC aggregates and analyzes data from public and licensed sources to deliver pharmaceutical intelligence. This policy describes our sourcing standards and attribution practices.

Primary Sources

We prioritize authoritative public sources including:

• Regulatory agencies: FDA (U.S.), EMA (EU), MHRA (UK), and comparable global authorities
• Clinical trial registries: ClinicalTrials.gov and equivalent international registries
• Patent offices: USPTO, EPO, and other public patent databases
• Company disclosures: SEC filings, press releases, and investor relations materials
• Scientific literature: PubMed-indexed publications and peer-reviewed journals

Attribution

Where data originates from public regulatory or government sources, we attribute the source and link to original records when available. Derived analysis, rankings, and proprietary indices are labeled as Nexvora editorial or analytical products.

Data Limitations

Public source data may contain delays, errors, or omissions. Regulatory databases are updated on varying schedules. Users should verify critical data against primary sources before making business or regulatory decisions.

Licensed and Third-Party Data

Some platform features may incorporate licensed third-party datasets subject to separate terms. Enterprise customers receive documentation of data sources applicable to their subscription tier.

What We Do Not Source

Nexvora does not collect, purchase, or process patient health records or individually identifiable patient data. We do not source data through unauthorized scraping of restricted systems.

Corrections

To report a data accuracy issue, contact [email protected] with the source reference and description of the discrepancy.